Gubra enters million-dollar agreement with big pharma
The Danish biotech company Gubra has announced a collaboration with a major German drug group for the development of novel peptide compounds. The deal has a potential value of EUR 250 million or approximately DKK 2 billion.
BY ELIZABETH MØNSTED JOHANSEN
Although Gubra only recently concluded an important collaboration with Sanofi, the Danish biotech company has already found a new partner.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech and CRO outfit Gubra continues explosive growth
For abonnenter
